FDA Approves Nivolumab as Adjuvant Treatment for Melanoma

WEDNESDAY, Oct. 18, 2023 -- The U.S. Food and Drug Administration has approved Opdivo (nivolumab) for the adjuvant treatment of completely resected stage IIB/C melanoma in patients ages 12 years and older. The approval was based on results from the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news